{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T04:15:48Z","timestamp":1730261748767,"version":"3.28.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiologie"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00117-024-01315-y","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T21:01:36Z","timestamp":1716411696000},"page":"536-545","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Klinische Bedeutung von neuroendokrinen Tumoren","Clinical significance of neuroendocrine tumors"],"prefix":"10.1007","volume":"64","author":[{"given":"Philipp E.","family":"Hartrampf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian E.","family":"Serfling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Bojunga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Weich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"issue":"4","key":"1315_CR1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/cncr.29099","volume":"121","author":"J Hallet","year":"2015","unstructured":"Hallet\u00a0J, Law\u00a0CH, Cukier\u00a0M, Saskin\u00a0R, Liu\u00a0N, Singh\u00a0S (2015) Exploring the rising incidence of neuroendocrine tumors: a\u00a0population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 121(4):589\u2013597","journal-title":"Cancer"},{"issue":"10","key":"1315_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari\u00a0A, Shen\u00a0C, Halperin\u00a0D, Zhao\u00a0B, Zhou\u00a0S, Xu\u00a0Y et\u00a0al (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3(10):1335\u20131342","journal-title":"JAMA Oncol"},{"issue":"6","key":"1315_CR3","doi-asserted-by":"publisher","first-page":"520","DOI":"10.5946\/ce.2017.181","volume":"50","author":"JL Chin","year":"2017","unstructured":"Chin\u00a0JL, O\u2019Toole\u00a0D (2017) Diagnosis and management of upper gastrointestinal neuroendocrine tumors. Clin Endosc 50(6):520\u2013529","journal-title":"Clin Endosc"},{"issue":"8","key":"1315_CR4","doi-asserted-by":"publisher","first-page":"e13318","DOI":"10.1111\/jne.13318","volume":"35","author":"J Hofland","year":"2023","unstructured":"Hofland\u00a0J, Falconi\u00a0M, Christ\u00a0E, Castano\u00a0JP, Faggiano\u00a0A, Lamarca\u00a0A et\u00a0al (2023) European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J\u00a0Neuroendocrinol 35(8):e13318","journal-title":"J Neuroendocrinol"},{"issue":"22","key":"1315_CR5","doi-asserted-by":"publisher","first-page":"6088","DOI":"10.7150\/thno.30357","volume":"8","author":"RA Werner","year":"2018","unstructured":"Werner\u00a0RA, Weich\u00a0A, Kircher\u00a0M, Solnes\u00a0LB, Javadi\u00a0MS, Higuchi\u00a0T et\u00a0al (2018) The theranostic promise for Neuroendocrine Tumors in the late 2010s\u2014Where do we stand, where do we go? Theranostics 8(22):6088\u20136100","journal-title":"Theranostics"},{"issue":"18","key":"1315_CR6","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao\u00a0JC, Hassan\u00a0M, Phan\u00a0A, Dagohoy\u00a0C, Leary\u00a0C, Mares\u00a0JE et\u00a0al (2008) One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J\u00a0Clin Oncol 26(18):3063\u20133072","journal-title":"J Clin Oncol"},{"issue":"6","key":"1315_CR7","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3322\/caac.21493","volume":"68","author":"M Cives","year":"2018","unstructured":"Cives\u00a0M, Strosberg\u00a0JR (2018) Gastroenteropancreatic Neuroendocrine Tumors. CA Cancer J Clin 68(6):471\u2013487","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"1315_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00423-011-0739-1","volume":"396","author":"S Schimmack","year":"2011","unstructured":"Schimmack\u00a0S, Svejda\u00a0B, Lawrence\u00a0B, Kidd\u00a0M, Modlin\u00a0IM (2011) The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbecks Arch Surg 396(3):273\u2013298","journal-title":"Langenbecks Arch Surg"},{"issue":"12","key":"1315_CR9","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.neo.2017.09.002","volume":"19","author":"B Oronsky","year":"2017","unstructured":"Oronsky\u00a0B, Ma\u00a0PC, Morgensztern\u00a0D, Carter\u00a0CA (2017) Nothing But NET: a\u00a0review of Neuroendocrine Tumors and Carcinomas. Neoplasia 19(12):991\u20131002","journal-title":"Neoplasia"},{"issue":"3","key":"1315_CR10","first-page":"176","volume":"19","author":"P Gut","year":"2015","unstructured":"Gut\u00a0P, Komarowska\u00a0H, Czarnywojtek\u00a0A, Waligorska-Stachura\u00a0J, Baczyk\u00a0M, Ziemnicka\u00a0K et\u00a0al (2015) Familial syndromes associated with neuroendocrine tumours. Contemp Oncol (pozn) 19(3):176\u2013183","journal-title":"Contemp Oncol (pozn)"},{"issue":"8","key":"1315_CR11","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/j.ejca.2012.12.022","volume":"49","author":"CM Korse","year":"2013","unstructured":"Korse\u00a0CM, Taal\u00a0BG, van Velthuysen\u00a0ML, Visser\u00a0O (2013) Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. Eur J Cancer 49(8):1975\u20131983","journal-title":"Eur J Cancer"},{"key":"1315_CR12","doi-asserted-by":"crossref","unstructured":"Takayanagi D, Cho H, Machida E, Kawamura A, Takashima A, Wada S et\u00a0al (2022) Update on epidemiology, diagnosis, and biomarkers in gastroenteropancreatic neuroendocrine neoplasms. Cancers (basel) 14(5)","DOI":"10.3390\/cancers14051119"},{"key":"1315_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000381970","volume":"44","author":"M Fraenkel","year":"2015","unstructured":"Fraenkel\u00a0M, Faggiano\u00a0A, Valk\u00a0GD (2015) Epidemiology of Neuroendocrine Tumors. Front Horm Res 44:1\u201323","journal-title":"Front Horm Res"},{"issue":"47","key":"1315_CR14","doi-asserted-by":"publisher","first-page":"9012","DOI":"10.3748\/wjg.v19.i47.9012","volume":"19","author":"H Scherubl","year":"2013","unstructured":"Scherubl\u00a0H, Streller\u00a0B, Stabenow\u00a0R, Herbst\u00a0H, Hopfner\u00a0M, Schwertner\u00a0C et\u00a0al (2013) Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany. World J Gastroenterol 19(47):9012\u20139019","journal-title":"World J Gastroenterol"},{"issue":"11","key":"1315_CR15","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41416-019-0606-3","volume":"121","author":"TSE Genus","year":"2019","unstructured":"Genus\u00a0TSE, Bouvier\u00a0C, Wong\u00a0KF, Srirajaskanthan\u00a0R, Rous\u00a0BA, Talbot\u00a0DC et\u00a0al (2019) Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a\u00a0UK nationwide cohort study 2013\u20132015. Br J Cancer 121(11):966\u2013972","journal-title":"Br J Cancer"},{"issue":"1","key":"1315_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/00365521.2018.1553061","volume":"54","author":"H Gudmundsdottir","year":"2019","unstructured":"Gudmundsdottir\u00a0H, Moller\u00a0PH, Jonasson\u00a0JG, Bjornsson\u00a0ES (2019) Gastroenteropancreatic neuroendocrine tumors in Iceland: a\u00a0population-based study. Scand J Gastroenterol 54(1):69\u201375","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"1315_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11912-021-01029-7","volume":"23","author":"S Das","year":"2021","unstructured":"Das\u00a0S, Dasari\u00a0A (2021) Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: are there Global Differences? Curr Oncol Rep 23(4):43","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"1315_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00535-014-0934-2","volume":"50","author":"T Ito","year":"2015","unstructured":"Ito\u00a0T, Igarashi\u00a0H, Nakamura\u00a0K, Sasano\u00a0H, Okusaka\u00a0T, Takano\u00a0K et\u00a0al (2015) Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a\u00a0nationwide survey analysis. J\u00a0Gastroenterol 50(1):58\u201364","journal-title":"J Gastroenterol"},{"issue":"1","key":"1315_CR19","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1186\/s12885-020-07581-y","volume":"20","author":"T Masui","year":"2020","unstructured":"Masui\u00a0T, Ito\u00a0T, Komoto\u00a0I, Uemoto\u00a0S, Group JPS (2020) Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a\u00a0population-based study. Bmc Cancer 20(1):1104","journal-title":"Bmc Cancer"},{"issue":"1","key":"1315_CR20","doi-asserted-by":"publisher","first-page":"7881","DOI":"10.1038\/s41598-021-86839-2","volume":"11","author":"JS Chang","year":"2021","unstructured":"Chang\u00a0JS, Chen\u00a0LT, Shan\u00a0YS, Chu\u00a0PY, Tsai\u00a0CR, Tsai\u00a0HJ (2021) An updated analysis of the epidemiologic trends of neuroendocrine tumors in Taiwan. Sci Rep 11(1):7881","journal-title":"Sci Rep"},{"issue":"3","key":"1315_CR21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.4143\/crt.2012.44.3.157","volume":"44","author":"MY Cho","year":"2012","unstructured":"Gastrointestinal Pathology Study Group of Korean Society of P, Cho\u00a0MY, Kim\u00a0JM, Sohn\u00a0JH, Kim\u00a0MJ, Kim\u00a0KM et\u00a0al (2012) Current trends of the incidence and pathological diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000\u20132009: multicenter study. Cancer Res Treat 44(3):157\u2013165","journal-title":"Cancer Res Treat"},{"issue":"1","key":"1315_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.beem.2011.06.005","volume":"26","author":"X Zarate","year":"2012","unstructured":"Zarate\u00a0X, Williams\u00a0N, Herrera\u00a0MF (2012) Pancreatic incidentalomas. Best Pract Res Clin Endocrinol Metab 26(1):97\u2013103","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"1315_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/MPA.0000000000001707","volume":"50","author":"E Kessel","year":"2021","unstructured":"Kessel\u00a0E, Naparst\u00a0M, Alpert\u00a0N, Diaz\u00a0K, Ahn\u00a0E, Wolin\u00a0E et\u00a0al (2021) Racial differences in Gastroenteropancreatic Neuroendocrine Tumor treatment and Survival in the United States. Pancreas 50(1):29\u201336","journal-title":"Pancreas"},{"issue":"18","key":"1315_CR24","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1093\/jnci\/djn275","volume":"100","author":"IM Modlin","year":"2008","unstructured":"Modlin\u00a0IM, Moss\u00a0SF, Chung\u00a0DC, Jensen\u00a0RT, Snyderwine\u00a0E (2008) Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J\u00a0Natl Cancer Inst 100(18):1282\u20131289","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"1315_CR25","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel\u00a0M, Oberg\u00a0K, Falconi\u00a0M, Krenning\u00a0EP, Sundin\u00a0A, Perren\u00a0A et\u00a0al (2020) Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31(7):844\u2013860","journal-title":"Ann Oncol"},{"issue":"6","key":"1315_CR26","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.gastro.2005.03.038","volume":"128","author":"IM Modlin","year":"2005","unstructured":"Modlin\u00a0IM, Kidd\u00a0M, Latich\u00a0I, Zikusoka\u00a0MN, Shapiro\u00a0MD (2005) Current status of gastrointestinal carcinoids. Gastroenterology 128(6):1717\u20131751","journal-title":"Gastroenterology"},{"issue":"1","key":"1315_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","volume":"9","author":"IM Modlin","year":"2008","unstructured":"Modlin\u00a0IM, Oberg\u00a0K, Chung\u00a0DC, Jensen\u00a0RT, de Herder\u00a0WW, Thakker\u00a0RV et\u00a0al (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9(1):61\u201372","journal-title":"Lancet Oncol"},{"issue":"10","key":"1315_CR28","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1634\/theoncologist.2019-0112","volume":"24","author":"J Hallet","year":"2019","unstructured":"Hallet\u00a0J, Davis\u00a0LE, Mahar\u00a0AL, Law\u00a0CHL, Isenberg-Grzeda\u00a0E, Bubis\u00a0LD et\u00a0al (2019) Patterns of Symptoms Burden in Neuroendocrine Tumors: a\u00a0population-based analysis of prospective patient-reported outcomes. Oncologist 24(10):1384\u20131394","journal-title":"Oncologist"},{"issue":"1","key":"1315_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.hoc.2015.08.006","volume":"30","author":"AI Vinik","year":"2016","unstructured":"Vinik\u00a0AI, Chaya\u00a0C (2016) Clinical Presentation and Diagnosis of Neuroendocrine Tumors. Hematol Oncol Clin North Am 30(1):21\u201348","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"1315_CR30","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1210\/endrev\/bnz004","volume":"41","author":"J Hofland","year":"2020","unstructured":"Hofland\u00a0J, Kaltsas\u00a0G, de Herder\u00a0WW (2020) Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. Endocr Rev 41(2):371\u2013403","journal-title":"Endocr Rev"},{"issue":"3","key":"1315_CR31","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1159\/000098012","volume":"84","author":"M Falconi","year":"2006","unstructured":"Falconi\u00a0M, Plockinger\u00a0U, Kwekkeboom\u00a0DJ, Manfredi\u00a0R, Korner\u00a0M, Kvols\u00a0L et\u00a0al (2006) Well-differentiated pancreatic nonfunctioning tumors\/carcinoma. Neuroendocrinology 84(3):196\u2013211","journal-title":"Neuroendocrinology"},{"issue":"9","key":"1315_CR32","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.2217\/fon.11.88","volume":"7","author":"T Liakakos","year":"2011","unstructured":"Liakakos\u00a0T, Roukos\u00a0DH (2011) Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors. Future Oncol 7(9):1025\u20131029","journal-title":"Future Oncol"},{"key":"1315_CR33","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mce.2013.08.002","volume":"386(1\u20132","author":"RV Thakker","year":"2014","unstructured":"Thakker\u00a0RV (2014) Multiple endocrine neoplasia type\u00a01 (MEN1) and type\u00a04 (MEN4). Mol Cell Endocrinol 386(1\u20132:2\u201315","journal-title":"Mol Cell Endocrinol"},{"issue":"11","key":"1315_CR34","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nrc2502","volume":"8","author":"WG Kaelin Jr.","year":"2008","unstructured":"Kaelin\u00a0WG Jr. (2008) The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8(11):865\u2013873","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1315_CR35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1677\/ERC-08-0142","volume":"16","author":"D Dworakowska","year":"2009","unstructured":"Dworakowska\u00a0D, Grossman\u00a0AB (2009) Are neuroendocrine tumours a\u00a0feature of tuberous sclerosis? a\u00a0systematic review. Endocr Relat Cancer 16(1):45\u201358","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"1315_CR36","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1093\/qjmed\/hcs203","volume":"108","author":"A Rogers","year":"2015","unstructured":"Rogers\u00a0A, Wang\u00a0LM, Karavitaki\u00a0N, Grossman\u00a0AB (2015) Neurofibromatosis Type\u00a01 and pancreatic islet cell tumours: an association which should be recognized. Qjm 108(7):573\u2013576","journal-title":"Qjm"},{"issue":"1","key":"1315_CR37","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ecl.2010.12.001","volume":"40","author":"B Lawrence","year":"2011","unstructured":"Lawrence\u00a0B, Gustafsson\u00a0BI, Kidd\u00a0M, Pavel\u00a0M, Svejda\u00a0B, Modlin\u00a0IM (2011) The clinical relevance of chromogranin a as a\u00a0biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 40(1):111\u2013134","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"4","key":"1315_CR38","doi-asserted-by":"publisher","first-page":"e0124884","DOI":"10.1371\/journal.pone.0124884","volume":"10","author":"X Yang","year":"2015","unstructured":"Yang\u00a0X, Yang\u00a0Y, Li\u00a0Z, Cheng\u00a0C, Yang\u00a0T, Wang\u00a0C et\u00a0al (2015) Diagnostic value of circulating chromogranin a\u00a0for neuroendocrine tumors: a\u00a0systematic review and meta-analysis. PLoS ONE 10(4):e124884","journal-title":"PLoS ONE"},{"key":"1315_CR39","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.regpep.2004.03.017","volume":"120(1\u20133","author":"L K\u00f6lby","year":"2004","unstructured":"K\u00f6lby\u00a0L, Bernhardt\u00a0P, Sw\u00e4rd\u00a0C, Johanson\u00a0V, Ahlman\u00a0H, Forssell-Aronsson\u00a0E et\u00a0al (2004) Chromogranin\u00a0a as a\u00a0determinant of midgut carcinoid tumour volume. Regul Pept 120(1\u20133:269\u2013273","journal-title":"Regul Pept"},{"key":"1315_CR40","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.regpep.2006.10.008","volume":"139(1\u20133","author":"M Stridsberg","year":"2007","unstructured":"Stridsberg\u00a0M, Eriksson\u00a0B, Fellstr\u00f6m\u00a0B, Kristiansson\u00a0G, Tiensuu Janson\u00a0E (2007) Measurements of chromogranin B can serve as a\u00a0complement to chromogranin A. Regul Pept 139(1\u20133:80\u201383","journal-title":"Regul Pept"},{"issue":"3","key":"1315_CR41","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1161\/01.HYP.15.3.237","volume":"15","author":"MA Takiyyuddin","year":"1990","unstructured":"Takiyyuddin\u00a0MA, Cervenka\u00a0JH, Hsiao\u00a0RJ, Barbosa\u00a0JA, Parmer\u00a0RJ, O\u2019Connor\u00a0DT (1990) Chromogranin\u00a0A. Storage and release in hypertension. Hypertension 15(3):237\u2013246","journal-title":"Hypertension"},{"issue":"5","key":"1315_CR42","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1530\/ERC-16-0524","volume":"24","author":"T Brabander","year":"2017","unstructured":"Brabander\u00a0T, van der Zwan\u00a0WA, Teunissen\u00a0JJM, Kam\u00a0BLR, de Herder\u00a0WW, Feelders\u00a0RA et\u00a0al (2017) Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [(177)Lu-DOTA(0),Tyr(3)]octreotate. Endocr Relat Cancer 24(5):243\u2013251","journal-title":"Endocr Relat Cancer"},{"issue":"839","key":"1315_CR43","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1136\/pgmj.71.839.542","volume":"71","author":"WP Tormey","year":"1995","unstructured":"Tormey\u00a0WP, FitzGerald\u00a0RJ (1995) The clinical and laboratory correlates of an increased urinary 5\u2011hydroxyindoleacetic acid. Postgrad Med\u00a0J 71(839):542\u2013545","journal-title":"Postgrad Med J"},{"issue":"2","key":"1315_CR44","doi-asserted-by":"publisher","first-page":"IJE17","DOI":"10.2217\/ije-2019-0001","volume":"6","author":"M Ewang-Emukowhate","year":"2019","unstructured":"Ewang-Emukowhate\u00a0M, Nair\u00a0D, Caplin\u00a0M (2019) The role of 5\u2011hydroxyindoleacetic acid in neuroendocrine tumors: the journey so far. Int J Endocr Oncol 6(2):IJE17","journal-title":"Int J Endocr Oncol"},{"issue":"6","key":"1315_CR45","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.bpg.2012.12.006","volume":"26","author":"G Kanakis","year":"2012","unstructured":"Kanakis\u00a0G, Kaltsas\u00a0G (2012) Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Best Pract Res Clin Gastroenterol 26(6):791\u2013802","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"5","key":"1315_CR46","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/(SICI)1097-0142(19990901)86:5<858::AID-CNCR23>3.0.CO;2-8","volume":"86","author":"E Bajetta","year":"1999","unstructured":"Bajetta\u00a0E, Ferrari\u00a0L, Martinetti\u00a0A, Celio\u00a0L, Procopio\u00a0G, Artale\u00a0S et\u00a0al (1999) Chromogranin\u00a0A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 86(5):858\u2013865","journal-title":"Cancer"},{"key":"1315_CR47","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/978-1-4939-3426-3_2","volume-title":"Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances","author":"S Seydafkan","year":"2016","unstructured":"Seydafkan\u00a0S, Coppola\u00a0D (2016) Neuroendocrine tumor classification systems: staging. In: Nasir\u00a0A, Coppola\u00a0D (Hrsg) Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances. Springer New York, New York, NY, S\u00a021\u201330"},{"issue":"6","key":"1315_CR48","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.gie.2012.01.011","volume":"75","author":"ASP Committee","year":"2012","unstructured":"Committee\u00a0ASP, Early\u00a0DS, Ben-Menachem\u00a0T, Decker\u00a0GA, Evans\u00a0JA, Fanelli\u00a0RD et\u00a0al (2012) Appropriate use of GI endoscopy. Gastrointest Endosc 75(6):1127\u20131131","journal-title":"Gastrointest Endosc"},{"issue":"6","key":"1315_CR49","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/MEG.0000000000001697","volume":"32","author":"G Esposito","year":"2020","unstructured":"Esposito\u00a0G, Angeletti\u00a0S, Cazzato\u00a0M, Galli\u00a0G, Conti\u00a0L, Di Giulio\u00a0E et\u00a0al (2020) Narrow band imaging characteristics of gastric polypoid lesions: a\u00a0single-center prospective pilot study. Eur J Gastroenterol Hepatol 32(6):701\u2013705","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"8","key":"1315_CR50","doi-asserted-by":"publisher","first-page":"e13306","DOI":"10.1111\/jne.13306","volume":"35","author":"F Panzuto","year":"2023","unstructured":"Panzuto\u00a0F, Ramage\u00a0J, Pritchard\u00a0DM, van Velthuysen\u00a0MF, Schrader\u00a0J, Begum\u00a0N et\u00a0al (2023) European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1\u2013G3. J\u00a0Neuroendocrinol 35(8):e13306","journal-title":"J Neuroendocrinol"},{"issue":"23","key":"1315_CR51","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.3748\/wjg.v19.i23.3678","volume":"19","author":"SR Puli","year":"2013","unstructured":"Puli\u00a0SR, Kalva\u00a0N, Bechtold\u00a0ML, Pamulaparthy\u00a0SR, Cashman\u00a0MD, Estes\u00a0NC et\u00a0al (2013) Diagnostic accuracy of endoscopic ultrasound in pancreatic neuroendocrine tumors: a\u00a0systematic review and meta analysis. World J Gastroenterol 19(23):3678\u20133684","journal-title":"World J Gastroenterol"},{"issue":"8","key":"1315_CR52","doi-asserted-by":"publisher","first-page":"e13318","DOI":"10.1111\/jne.13318","volume":"35","author":"J Hofland","year":"2023","unstructured":"Hofland\u00a0J, Falconi\u00a0M, Christ\u00a0E, Casta\u00f1o\u00a0JP, Faggiano\u00a0A, Lamarca\u00a0A et\u00a0al (2023) European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J\u00a0Neuroendocrinol 35(8):e13318","journal-title":"J Neuroendocrinol"},{"issue":"2","key":"1315_CR53","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000443166","volume":"103","author":"JK Ramage","year":"2016","unstructured":"Ramage\u00a0JK, De Herder\u00a0WW, Delle Fave\u00a0G, Ferolla\u00a0P, Ferone\u00a0D, Ito\u00a0T et\u00a0al (2016) ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms. Neuroendocrinology 103(2):139\u2013143","journal-title":"Neuroendocrinology"},{"issue":"11","key":"1315_CR54","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.3748\/wjg.v23.i11.2037","volume":"23","author":"SB Park","year":"2017","unstructured":"Park\u00a0SB, Kim\u00a0DJ, Kim\u00a0HW, Choi\u00a0CW, Kang\u00a0DH, Kim\u00a0SJ et\u00a0al (2017) Is endoscopic ultrasonography essential for endoscopic resection of small rectal neuroendocrine tumors? World J Gastroenterol 23(11):2037\u20132043","journal-title":"World J Gastroenterol"},{"issue":"2","key":"1315_CR55","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1159\/000358727","volume":"99","author":"C Toumpanakis","year":"2014","unstructured":"Toumpanakis\u00a0C, Kim\u00a0MK, Rinke\u00a0A, Bergestuen\u00a0DS, Thirlwell\u00a0C, Khan\u00a0MS et\u00a0al (2014) Combination of cross-sectional and molecular imaging studies in the localization of gastroenteropancreatic neuroendocrine tumors. Neuroendocrinology 99(2):63\u201374","journal-title":"Neuroendocrinology"},{"issue":"3","key":"1315_CR56","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1159\/000471879","volume":"105","author":"A Sundin","year":"2017","unstructured":"Sundin\u00a0A, Arnold\u00a0R, Baudin\u00a0E, Cwikla\u00a0JB, Eriksson\u00a0B, Fanti\u00a0S et\u00a0al (2017) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine & hybrid imaging. Neuroendocrinology 105(3):212\u2013244","journal-title":"Neuroendocrinology"},{"issue":"78","key":"1315_CR57","doi-asserted-by":"publisher","first-page":"228","DOI":"10.15557\/JoU.2019.0034","volume":"19","author":"J Walczyk","year":"2019","unstructured":"Walczyk\u00a0J, Sowa-Staszczak\u00a0A (2019) Diagnostic imaging of gastrointestinal neuroendocrine neoplasms with a\u00a0focus on ultrasound. J\u00a0Ultrason 19(78):228\u2013235","journal-title":"J Ultrason"},{"key":"1315_CR58","doi-asserted-by":"crossref","unstructured":"El Gabry M, Arends S, Shehada SE, Lahner H, Kamler M, Wendt D et\u00a0al (2023) Hedinger syndrome-lessons learnt: a\u00a0single-center experience. J\u00a0Cardiovasc Dev Dis 10(10)","DOI":"10.3390\/jcdd10100413"},{"issue":"1","key":"1315_CR59","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1200\/JCO.2005.01.013","volume":"23","author":"C Dromain","year":"2005","unstructured":"Dromain\u00a0C, de Baere\u00a0T, Lumbroso\u00a0J, Caillet\u00a0H, Laplanche\u00a0A, Boige\u00a0V et\u00a0al (2005) Detection of liver metastases from endocrine tumors: a\u00a0prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J\u00a0Clin Oncol 23(1):70\u201378","journal-title":"J Clin Oncol"},{"issue":"12","key":"1315_CR60","doi-asserted-by":"publisher","first-page":"6593","DOI":"10.1007\/s00330-020-06930-6","volume":"30","author":"R Hayoz","year":"2020","unstructured":"Hayoz\u00a0R, Vietti-Violi\u00a0N, Duran\u00a0R, Knebel\u00a0JF, Ledoux\u00a0JB, Dromain\u00a0C (2020) The combination of hepatobiliary phase with Gd-EOB-DTPA and DWI is highly accurate for the detection and characterization of liver metastases from neuroendocrine tumor. Eur Radiol 30(12):6593\u20136602","journal-title":"Eur Radiol"},{"issue":"6","key":"1315_CR61","doi-asserted-by":"publisher","first-page":"e13309","DOI":"10.1111\/jne.13309","volume":"35","author":"A Rinke","year":"2023","unstructured":"Rinke\u00a0A, Ambrosini\u00a0V, Dromain\u00a0C, Garcia-Carbonero\u00a0R, Haji\u00a0A, Koumarianou\u00a0A et\u00a0al (2023) European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours. J\u00a0Neuroendocrinol 35(6):e13309","journal-title":"J Neuroendocrinol"},{"issue":"18","key":"1315_CR62","first-page":"5969","volume":"50","author":"JC Reubi","year":"1990","unstructured":"Reubi\u00a0JC, Kvols\u00a0LK, Waser\u00a0B, Nagorney\u00a0DM, Heitz\u00a0PU, Charboneau\u00a0JW et\u00a0al (1990) Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 50(18):5969\u20135977","journal-title":"Cancer Res"},{"issue":"1","key":"1315_CR63","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2967\/jnumed.117.202275","volume":"59","author":"TA Hope","year":"2018","unstructured":"Hope\u00a0TA, Bergsland\u00a0EK, Bozkurt\u00a0MF, Graham\u00a0M, Heaney\u00a0AP, Herrmann\u00a0K et\u00a0al (2018) Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors. J\u00a0Nucl Med 59(1):66\u201374","journal-title":"J Nucl Med"},{"issue":"12","key":"1315_CR64","doi-asserted-by":"publisher","first-page":"e13343","DOI":"10.1111\/jne.13343","volume":"35","author":"B Kos-Kud\u0142a","year":"2023","unstructured":"Kos-Kud\u0142a\u00a0B, Casta\u00f1o\u00a0JP, Denecke\u00a0T, Grande\u00a0E, Kjaer\u00a0A, Koumarianou\u00a0A, et\u00a0al European Neuroendocrine Tumour Society (2023) (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. J\u00a0Neuroendocrinol 35(12):e13343","journal-title":"J Neuroendocrinol"},{"issue":"7","key":"1315_CR65","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1097\/MPA.0000000000001589","volume":"49","author":"DL Chan","year":"2020","unstructured":"Chan\u00a0DL, Hoang\u00a0J, Roach\u00a0PJ, Arena\u00a0J, Bailey\u00a0DL, Nevell\u00a0D et\u00a0al (2020) Routine Early 68Ga-DOTATATE positron emission tomography has low yield after resection of appendiceal neuroendocrine neoplasms. Pancreas 49(7):891\u2013896","journal-title":"Pancreas"},{"issue":"10","key":"1315_CR66","doi-asserted-by":"publisher","first-page":"e13332","DOI":"10.1111\/jne.13332","volume":"35","author":"G Kaltsas","year":"2023","unstructured":"Kaltsas\u00a0G, Walter\u00a0T, Knigge\u00a0U, Toumpanakis\u00a0C, Santos\u00a0AP, Begum\u00a0N et\u00a0al (2023) European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for appendiceal neuroendocrine tumours (aNET). J\u00a0Neuroendocrinol 35(10):e13332","journal-title":"J Neuroendocrinol"},{"issue":"1","key":"1315_CR67","doi-asserted-by":"publisher","first-page":"e13359","DOI":"10.1111\/jne.13359","volume":"36","author":"V Ambrosini","year":"2024","unstructured":"Ambrosini\u00a0V, Caplin\u00a0M, Casta\u00f1o\u00a0JP, Christ\u00a0E, Denecke\u00a0T, Deroose\u00a0CM et\u00a0al (2024) Use and perceived utility of [(18) F]FDG PET\/CT in neuroendocrine neoplasms: a\u00a0consensus report from the European Neuroendocrine Tumor Society (ENETS) advisory board meeting 2022. J\u00a0Neuroendocrinol 36(1):e13359","journal-title":"J Neuroendocrinol"},{"issue":"1","key":"1315_CR68","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/RLU.0000000000004480","volume":"48","author":"A Kosmala","year":"2023","unstructured":"Kosmala\u00a0A, Serfling\u00a0SE, Schlotelburg\u00a0W, Lindner\u00a0T, Michalski\u00a0K, Schirbel\u00a0A et\u00a0al (2023) Impact of 68\u202fGa-FAPI-04 PET\/CT on staging and therapeutic management in patients with digestive system tumors. Clin Nucl Med 48(1):35\u201342","journal-title":"Clin Nucl Med"},{"issue":"7","key":"1315_CR69","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1023\/A:1008215730767","volume":"8","author":"ET Janson","year":"1997","unstructured":"Janson\u00a0ET, Holmberg\u00a0L, Stridsberg\u00a0M, Eriksson\u00a0B, Theodorsson\u00a0E, Wilander\u00a0E et\u00a0al (1997) Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a\u00a0referral center. Ann Oncol 8(7):685\u2013690","journal-title":"Ann Oncol"},{"issue":"8","key":"1315_CR70","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.21037\/tcr-23-248","volume":"12","author":"Z Tao","year":"2023","unstructured":"Tao\u00a0Z, Xue\u00a0R, Wei\u00a0Z, Qin\u00a0L, Bai\u00a0R, Liu\u00a0N et\u00a0al (2023) The assessment of Ki-67 for prognosis of gastroenteropancreatic neuroendocrine neoplasm patients: a\u00a0systematic review and meta-analysis. Transl Cancer Res 12(8):1980\u20131991","journal-title":"Transl Cancer Res"},{"key":"1315_CR71","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1159\/000503722","volume":"110(7\u20138","author":"A Busico","year":"2020","unstructured":"Busico\u00a0A, Maisonneuve\u00a0P, Prinzi\u00a0N, Pusceddu\u00a0S, Centonze\u00a0G, Garzone\u00a0G et\u00a0al (2020) Gastroenteropancreatic high-grade neuroendocrine neoplasms: histology and molecular analysis, two sides of the same coin. Neuroendocrinology 110(7\u20138:616\u2013629","journal-title":"Neuroendocrinology"},{"key":"1315_CR72","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/MPA.0000000000000032","volume":"43(2","author":"F Panzuto","year":"2014","unstructured":"Panzuto\u00a0F, Merola\u00a0E, Rinzivillo\u00a0M, Partelli\u00a0S, Campana\u00a0D, Iannicelli\u00a0E et\u00a0al (2014) Advanced digestive neuroendocrine tumors: metastatic pattern is an independent factor affecting clinical outcome. Pancreas 43(2:212\u2013218","journal-title":"Pancreas"},{"issue":"1","key":"1315_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ecl.2010.12.005","volume":"40","author":"B Lawrence","year":"2011","unstructured":"Lawrence\u00a0B, Gustafsson\u00a0BI, Chan\u00a0A, Svejda\u00a0B, Kidd\u00a0M, Modlin\u00a0IM (2011) The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 40(1):1\u201318 (vii)","journal-title":"Endocrinol Metab Clin North Am"},{"key":"1315_CR74","doi-asserted-by":"publisher","first-page":"5629","DOI":"10.2147\/CMAR.S174907","volume":"10","author":"D Man","year":"2018","unstructured":"Man\u00a0D, Wu\u00a0J, Shen\u00a0Z, Zhu\u00a0X (2018) Prognosis of patients with neuroendocrine tumor: a\u00a0SEER database analysis. Cancer Manag Res 10:5629\u20135638","journal-title":"Cancer Manag Res"},{"issue":"6","key":"1315_CR75","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s00268-011-1296-z","volume":"36","author":"O Norlen","year":"2012","unstructured":"Norlen\u00a0O, Stalberg\u00a0P, Oberg\u00a0K, Eriksson\u00a0J, Hedberg\u00a0J, Hessman\u00a0O et\u00a0al (2012) Long-term results of surgery for small intestinal neuroendocrine tumors at a\u00a0tertiary referral center. World J Surg 36(6):1419\u20131431","journal-title":"World J Surg"},{"key":"1315_CR76","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3389\/fendo.2018.00146","volume":"9","author":"S Exner","year":"2018","unstructured":"Exner\u00a0S, Prasad\u00a0V, Wiedenmann\u00a0B, Grotzinger\u00a0C (2018) Octreotide does not inhibit proliferation in five neuroendocrine tumor cell lines. Front Endocrinol (lausanne) 9:146","journal-title":"Front Endocrinol (lausanne)"},{"issue":"4","key":"1315_CR77","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1124\/pr.117.015388","volume":"70","author":"T Gunther","year":"2018","unstructured":"Gunther\u00a0T, Tulipano\u00a0G, Dournaud\u00a0P, Bousquet\u00a0C, Csaba\u00a0Z, Kreienkamp\u00a0HJ et\u00a0al (2018) International Union of basic and clinical pharmacology. CV. Somatostatin Receptors: structure, function, ligands, and new nomenclature. Pharmacol Rev 70(4):763\u2013835","journal-title":"Pharmacol Rev"},{"issue":"12","key":"1315_CR78","first-page":"2250","volume":"92","author":"SB Saslow","year":"1997","unstructured":"Saslow\u00a0SB, O\u2019Brien\u00a0MD, Camilleri\u00a0M, von der Ohe\u00a0M (1997) Homburger HA, Klee GG, et\u00a0al. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome. Am J Gastroenterol 92(12):2250\u20132256","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"1315_CR79","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/MPA.0000000000000762","volume":"46","author":"F Panzuto","year":"2017","unstructured":"Panzuto\u00a0F, Rinzivillo\u00a0M, Spada\u00a0F, Antonuzzo\u00a0L, Ibrahim\u00a0T, Campana\u00a0D et\u00a0al (2017) Everolimus in pancreatic neuroendocrine carcinomas G3. Pancreas 46(3):302\u2013305","journal-title":"Pancreas"},{"issue":"1","key":"1315_CR80","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1159\/000487237","volume":"107","author":"A Pellat","year":"2018","unstructured":"Pellat\u00a0A, Dreyer\u00a0C, Couffignal\u00a0C, Walter\u00a0T, Lombard-Bohas\u00a0C, Niccoli\u00a0P et\u00a0al (2018) Clinical and biomarker evaluations of sunitinib in patients with grade\u00a03 digestive neuroendocrine neoplasms. Neuroendocrinology 107(1):24\u201331","journal-title":"Neuroendocrinology"},{"issue":"8","key":"1315_CR81","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/sj.bjc.6690325","volume":"81","author":"E Mitry","year":"1999","unstructured":"Mitry\u00a0E, Baudin\u00a0E, Ducreux\u00a0M, Sabourin\u00a0JC, Rufie\u00a0P, Aparicio\u00a0T et\u00a0al (1999) Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 81(8):1351\u20131355","journal-title":"Br J Cancer"},{"issue":"2","key":"1315_CR82","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000443172","volume":"103","author":"R Garcia-Carbonero","year":"2016","unstructured":"Garcia-Carbonero\u00a0R, Sorbye\u00a0H, Baudin\u00a0E, Raymond\u00a0E, Wiedenmann\u00a0B, Niederle\u00a0B et\u00a0al (2016) ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology 103(2):186\u2013194","journal-title":"Neuroendocrinology"},{"issue":"2","key":"1315_CR83","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s12149-010-0444-0","volume":"25","author":"L Nisa","year":"2011","unstructured":"Nisa\u00a0L, Savelli\u00a0G, Giubbini\u00a0R (2011) Yttrium-90 DOTATOC therapy in GEP-NET and other SST2 expressing tumors: a\u00a0selected review. Ann Nucl Med 25(2):75\u201385","journal-title":"Ann Nucl Med"},{"issue":"2","key":"1315_CR84","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg\u00a0J, El-Haddad\u00a0G, Wolin\u00a0E, Hendifar\u00a0A, Yao\u00a0J, Chasen\u00a0B et\u00a0al (2017) Phase\u00a03 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N\u00a0Engl J Med 376(2):125\u2013135","journal-title":"N Engl J Med"},{"issue":"25","key":"1315_CR85","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1200\/JCO.2018.78.5865","volume":"36","author":"J Strosberg","year":"2018","unstructured":"Strosberg\u00a0J, Wolin\u00a0E, Chasen\u00a0B, Kulke\u00a0M, Bushnell\u00a0D, Caplin\u00a0M et\u00a0al (2018) Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with (177)Lu-Dotatate in the Phase\u00a0III NETTER\u20111 trial. J\u00a0Clin Oncol 36(25):2578\u20132584","journal-title":"J Clin Oncol"},{"issue":"12","key":"1315_CR86","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg\u00a0JR, Caplin\u00a0ME, Kunz\u00a0PL, Ruszniewski\u00a0PB, Bodei\u00a0L, Hendifar\u00a0A et\u00a0al (2021) (177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase\u00a03\u00a0trial. Lancet Oncol 22(12):1752\u20131763","journal-title":"Lancet Oncol"}],"container-title":["Die Radiologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-024-01315-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00117-024-01315-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-024-01315-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T13:03:33Z","timestamp":1730207013000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00117-024-01315-y"}},"subtitle":["H\u00e4ufigkeit, Symptome, Diagnose und Stadien und prognostische Faktoren und deren Einfluss auf das Krankheitsmanagement","Incidence, symptoms, diagnosis, stage, and prognostic factors and their influence on disease management"],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":86,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1315"],"URL":"https:\/\/doi.org\/10.1007\/s00117-024-01315-y","relation":{},"ISSN":["2731-7048","2731-7056"],"issn-type":[{"type":"print","value":"2731-7048"},{"type":"electronic","value":"2731-7056"}],"subject":[],"published":{"date-parts":[[2024,5,22]]},"assertion":[{"value":"24 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"R.A.\u00a0Werner hat Rednerhonorare von Novartis\/AAA und PentixaPharm erhalten und war im Advisory Board von Novartis\/AAA und Bayer t\u00e4tig. AW hat Rednerhonorare von Novartis\/AAA erhalten und war im Advisory Board von Novartis\/AAA t\u00e4tig. P.E.\u00a0Hartrampf, S.E.\u00a0Serfling, T.\u00a0Higuchi, J.\u00a0Bojunga und A.\u00a0Weich geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}